依折麦布治疗非酒精性脂肪肝患者的疗效观察

Clinical effects of ezetimibe on the treatment of patients with nonalcoholic fatty liver disease

目的观察依折麦布治疗非酒精性脂肪肝患者的临床疗效。方法选取2020年4月至2021年10月在九江市第三人医院诊治的56例非酒精性脂肪肝患者,随机分为试验组和对照组,试验组在对照组用药基础上加用依折麦布辅助强化调脂,连续治疗48周。比较两组患者治疗前后临床疗效、血清生化指标和肝脏硬度值的差异。结果治疗48周后,试验组临床总有效率为92.85%(26/28),优于对照组的67.85%(19/28),差异有统计学意义(χ^(2)=5.543,P=0.019)。治疗后试验组血清ALT、AST、γ-GT、TC、TG、LDL-C指标均低于对照组(P<0.05),试验组肝脏硬度值为(6.21±0.99)kPa,低于对照组的(6.79±1.05)kPa,差异有统计学意义(t=-2.109,P=0.040)。结论依折麦布通过调控胆固醇代谢,可改善肝酶指标和肝脏纤维化程度,提高非酒精性脂肪肝患者的临床疗效。

Objective To evaluate the clinic efficacy of ezetimibe in treating patients with nonalcoholic fatty liver disease(NAFLD).Methods From April 2020 to october 2021,56 patients with NAFLD were selected and randomly divided into experimental group and control group.The experimental group was given ezetimibe in addition to the treatment received by the control group,in order to regualte cholesterol metabolism.The treatment course lasted 48 weeks.Clinical effficacy,serum biochemical indicators,and liver stiffness values were observed and compared before and after the treatment.Results After 48 weeks of treatment,the total curative effects in the experimental group and control groups were 92.85%and 67.85%,respectively.The difference was statistically significant(P<0.05).The levels of ALT,AST,γ-GT,TC,TG,LDL-C in the experimental group were lower than those in the control group,with the differences being statistically significant(P<0.05).The liver stiffness value of the experimental group was lower than that of the control group after treatment,showing a significant difference between the two groups(6.21±0.99 kPa vs.6.79±1.05 kPa,P<0.05).Conclusion Ezetimibe,by regulating cholesterol metabolism,can enhance liver function indices and reduce liver stiffness,thereby improving the clinical outcomes for patients with NAFLD.